Vanguard Group
PTHS

Vanguard Group’s Pelthos Therapeutics PTHS Stock Holding History

Vanguard Group’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.33M Buy
75,020
+8,184
+12% +$236K ﹤0.01% 3513
2025
Q3 		$1.87M Buy
+66,836
New +$1.62M ﹤0.01% 3601

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Vanguard Group's PTHS Position: Q4 2025 in Review

Vanguard Group increased its Pelthos Therapeutics (PTHS) stake by 12% in Q4 2025, buying an estimated $236K and bringing the position to 75,020 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3513.

Vanguard Group first reported a position in PTHS in Q3 2025 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold PTHS as of Q4 2025.

  • Vanguard Group held 75,020 shares of Pelthos Therapeutics worth $2.33M as of Q4 2025.
  • Vanguard Group bought 8,184 Pelthos Therapeutics shares in Q4 2025, an estimated $236K.
  • Pelthos Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3513 holding.
  • Vanguard Group first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.